• 제목/요약/키워드: Candidiasis

검색결과 131건 처리시간 0.027초

구강내 연조직 질환과 구강점막 각화도와의 관계 (A Study of the Relationship between Keratinization of Oral Mucosa and Intraoral Soft Tissue Disease)

  • 송주종;김병국;최홍란
    • Journal of Oral Medicine and Pain
    • /
    • 제26권1호
    • /
    • pp.1-10
    • /
    • 2001
  • To investigate the relationship between several intraoral soft tissue lesions(hairy tongue, lichen planus, recurrent aphthous stomatitis, oral candidiasis, glossitis and oral herpetic lesion) and oral mucosal keratinization, exfoliative cytological smear on intraoral mucosal surfaces were performed on each number of patients and 25 controls keratinization cell (yellow-stained cell) ratio was then measured. In hairy tongue, there was no significant difference between patient group and control group in all kind of cells. Only blue cell ratio of women was more than of men in patient group. In lichen planus, there was no difference between patient and control group in yellow cell ratio. Red cell ratio in the control group was more than in the patient group. Blue cell ratio in the patient group was more than that in control group. But there was no sex predilection between both groups in the ratio of all kind of cells. In recurrent aphthous stomatitis, Yellow cell ratio in the control group was more than that in the patient group. Red cell ratio in the control group was more than that in control group. Blue cell ratio in the patient group was more than that in control group. But there was no sex predilection between both groups in the ratio of all kind of cells. In oral candidiasis, Yellow cell ratio in the control group was more than that in the patient group. Red cell ratio in the control group was more than that in control group. Blue cell ratio in the patient group was more than that in control group. There was no sex predilection between both groups in yellow cell ratio. Red cell ratio of women was more than of men in patient group. Blue cell ratio of men was more than of women in patient group. In herpetic lesions, there was no difference between patient and control group in yellow cell ratio. Red cell ratio in the control group was more than in the patient group. Blue cell ratio in the patient group was more than that in control group. Yellow cell ratio of women was more than of men in control group. Red cell ratio of men was more than of women in control group. Blue cell ratio of men was more than of women in patient group. In glossitis, Yellow cell ratio in the control group was more than in the patient group. There was no difference between patient and control group in red cell ratio. Blue cell ratio in the patient group was more than that in control group. Yellow cell ratio of women was more than of men in control group. Red cell ratio and blue cell ratio of men were more than of women in control group. According to above results, the ratio of keratinized cell in atrophic, ulcerated, or pseudomembranous lesions was lowered than in control, but the ratio of keratinized cell in keratotic, vesicular or lesions on keratinized surface lesions had no difference to control group. Thus, keratotic, vesicular or lesions on keratinized surface lesions have not closely relation to mucosal keratinization. And, there was a little sex predilection between men and wemen in mucosal keratinization.

  • PDF

디푸루칸 캡슐 50 mg (3 캡슐, 플루코나졸 150mg)에 대한 푸루나졸 정 150mg의 생물학적 동등성 (The Bioequivalence of Plunazol Tablet (Fluconazole 150 mg) to Three capsules of Diflucan 50 mg)

  • 장희철;이민석;유정현;류승효;조상헌;최연진;황애경;김윤아;박시현;윤지원;배균섭
    • Journal of Pharmaceutical Investigation
    • /
    • 제39권3호
    • /
    • pp.207-216
    • /
    • 2009
  • Fluconazole is used as an orally administrated antifungal drug for the treatment of tinea corporis, candidiasis including skin mycotic pneumonia infections. The dosage of fluconazole varies with indication ranging from 50 mg/day to 400 mg/day. The fluconazole capsule 50 mg (3 capsules daily) is already available in Korean market. To improve the patient compliance, a fluconazole tablet 150 mg (once a day administration) was developed recently. The purpose of this study was to evaluate the bioequivalence of three doses of fluconazole capsule 50 mg (Diflucan 50 mg, Pfizer Korea Inc., as a reference drug) and a single dose of fluconazole tablet 150 mg (Plunazol 150 mg, Daewoong Pharm. Co., Korea) according to the guidelines of the Korea Food and Drug Administration (KFDA). The bioequivalence for three capsules of Diflucan 50 mg and a single tablet of Plunazol 150 mg was investigated in twenty-four healthy male volunteers under a randomized 2${\times}$2 crossover trial design. The average age of twenty-four volunteers was 24.78${\pm}$3.27 year-old, average height was 175.56${\pm}$5.45 cm and average weight was 67.24${\pm}$6.86 kg. After three capsules of Diflucan 50 mg or a single tablet of Plunazol 150 mg were orally administered, blood was taken at predetermined time intervals and the plasma concentrations of fluconazole in plasma were determined using LC-MS-MS. The 90% confidence intervals for the main parameters of statistical results after logarithmic transformation were AUCt 0.9272-1.0084 and Cmax 0.8423-0.9544 respectively, which are in the range of log 0.8 to log 1.25 and the statistical results of additional parameters (AUClast, t1/2 and MRT) were also in the 90% confidence interval that is in the range of log 0.8 to log 1.25. Therefore, the results of this study confirm the bioequivalence of three capsules of Diflucan 50 mg to one tablet of Plunazol 150 mg.

중증 근무력증 환자의 임상적 고찰 (A Clinical Study of Management In Myasthenia Gravis)

  • 김훈;이두연;조범구;홍승록;선우일남
    • Journal of Chest Surgery
    • /
    • 제20권1호
    • /
    • pp.112-127
    • /
    • 1987
  • Myasthenia gravis is a neuromuscular transmission function disorder characterized by fatigue and weakness of voluntary muscles. This muscular weakness is intensified by activity and stress, and improved by the use of anticholinesterase compounds. It was initially described by Erb in 1879 and later named myasthenia gravis by Jolly in 1895. Although the pathogenesis is Known to be an autoimmune related reduction in the number of available acetylcholine receptors at neuromuscular junctions, the role of thymus in myasthenia gravis is still unclear and under investigation. Thymectomy in the management of myasthenia gravis has become increasingly important since Dr. Blalock observed in 1939 that some patients with thymic tumors and myasthenia gravis improved following thymectomy. A clinical study of 102 cases of myasthenia gravis was performed at Yonsei University College of Medicine. Seoul, Korea from Jan. 1976 to Jun. 1986. In order to determine which factors are of prognostic significance, attention is focused upon pre-operative patient evaluation, problems in operative and post-operative care, and long-term follow-up observations. The results were as follows: 1. The sex distribution was 67 females and 35 males, the mean age of onset was 28.95*1.69 years, and the maximal incidence occurred between 21 and 40 years of age [56 cases: 54.9%]. 2. Clinical manifestations of ocular symptoms were seen to 70 patients [68.6%] extremities weakness in 33 [32.3%], bulbar weakness in 29 [28.4%], and dyspnea in 13 [12.7%]. 3. Study cases more than two thirds were classified as mild types [MG 1 and MG 11A] and 6 cases as grave [MG 1V] based on the modified Osserman`s classification system, 4. Thymectomy was performed in 19 cases which presented in severe myasthenia symptoms and showed no improvement with cholinergic drugs. Histologic examination of the excised thymus glands revealed no abnormalities in 4 cases, thymic hyperplasia in 5, benign thymoma in 5, and malignant thymoma in 5. 5. Immediate post-operative complications included 2 cases of pneumothorax which were treated by tube thoracostomies, there was no operative mortality. 6. The response to cholinergic drugs in 36 cases younger than 20 years old and in 27 cases older than 40 years was relatively poor, while that in 35 cases between the ages of 21 and 40 years old was good. 7. Thirty of 39 cases in groups IIB, III & IV improved markedly with medical or surgical management while only 16 of 59 cases in the mild groups [I and IIA] improved, almost all surgical cases improved in all categories. 8. There were 5 deaths. occurring between 7 months and 3 years 3 months of treatment of myasthenia gravis. The causes of death were myasthenic crisis in 2 cases, respiratory failure due to candidiasis & radiation pneumonitis in one case, cerebral hemorrhage due to high blood pressure in two case.

  • PDF

디푸루칸 캅셀(플루코나졸 50 mg)에 대한 플루코나 캅셀의 생물학적 동등성 (Bioequivalence of Flucona Capsule to Diflucan Capsule (Fluconazole 50 mg))

  • 조혜영;강현아;이석;오인준;임동구;문재동;이용복
    • Journal of Pharmaceutical Investigation
    • /
    • 제33권2호
    • /
    • pp.135-140
    • /
    • 2003
  • Fluconazole is an orally active bis-triazole antifungal agent, which is used in the treatment of superficial and systemic candidiasis and in the treatment of cryptococcal infections in patients with the acquired immuno deficiency syndrome (AIDS). The purpose of the present study was to evaluate the bioequivalence of two fluconazole capsules, Diflucan (Pfizer Pharmaceuticals Korea Inc.) and Flucona (Korean Drug Pharmaceuticals Co., Ltd.), according to the guidelines of Korea Food and Drug Administration (KFDA). The fluconazole release from the two fluconazole capsules in vitro was tested using KP VII Apparatus II method at 0.1 M hydrochloride dissolution media. Twenty normal male volunteers, $23.60{\pm}1.88$ years in age and $63.57{\pm}6.17\;kg$ in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After three capsules containing 50 mg as fluconazole was orally administered, blood was taken at predetermined time intervals and the concentrations of fluconazole in serum were determined using HPLC method with UV detector. The dissolution profiles of two fluconazole capsules were very similar at 0.1 M hydrochloride dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$ and $C_{max}$ and untransformed $T_{max}$. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two capsules based on the Diflucan were 4.96%, 5.65% and -13.76%, respectively. There were no sequence effects between two capsules in these parameter. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) $(e.g.,\;log(1.01){\sim}log(1.08)\;and\;log(1.00){\sim}log(1.12)\;for\;AUC_t\;and\;C_{max},\;respectively)$, indicating that Flucona capsule is bioequivalent to Diflucan capsule.

구강 캔디다증 알비칸스에 대한 프로 폴리스의 항균 활동 -프로폴리스를 이용한 미생물 억제 효과- (Antimicrobial Activities of Propolis against Oral Candidiasis by Candida Albicans -Effect of Microbial Inhibition Using Propolis-)

  • 권현숙;남설희;박민경;조미숙;천세희
    • 한국산학기술학회논문지
    • /
    • 제15권9호
    • /
    • pp.5644-5651
    • /
    • 2014
  • 본 연구는 칸디다 알비칸스(C. albicans)에 대한 프로폴리스의 억제효과를 확인하고자 수행되었다. 프로폴리스는 양봉 꿀벌에서 채취하여 C. albicans는 $37^{\circ}C$에서 액체 배지에서 2시간 배양 하였다. 항균 활성검삼를 위해서 생리식염수 (PBS), 3% 차아염소산나트륨 (NaOCl에), 0.1% 클로로헥시딘 (CHX), 프로 폴리스 추출물 ($5{\mu}L/m{\ell}$, $10{\mu}L/m{\ell}$)에서 평가하였다. C. albicans는 3%의 NaOCl, 0.1% CHX, 프로 폴리스($5{\mu}L/m{\ell}$, $10{\mu}{\ell}/m{\ell}$)에서 15, 14.5, 16, 17mm의 억제구간을 확인하였다. 항균활성을 확인하기 위하여 집락형성을 분석한 결과, 3%의 NaOCl, 0.1 % CHX, $5{\mu}L/m{\ell}$$10{\mu}L/m{\ell}$의 프로 폴리스가 7, 7, 5, 7 로그지수가 감소를 보였다. C. albicans서는 $10{\mu}L/m{\ell}$의 프로폴리스에서 유의하게 억제되는 결과를 보여주었다. 이러한 결과를 통하여 프로폴리스는 구강 점막 질환에서 새로운 향균 약제가 될수 있는 것으로 생각된다.

편백 피톤치드가 Candida albicans에 미치는 영향에 대한 연구 (Effect of Chamaecyparis obtusa tree Phytoncide on Candida albicans)

  • 강수경;어규식;전양현;홍정표
    • Journal of Oral Medicine and Pain
    • /
    • 제35권1호
    • /
    • pp.19-29
    • /
    • 2010
  • 나무가 갖는 특유의 향인 피톤치드는 휘발성 화학물질로서, 식물이 방어를 위해 스스로 생성하여 발산하는 물질이며, 항균, 방충, 소취 등 다양한 기능을 가지고 있는 천연 물질이다. 편백나무(Chamaecyparis obtusa Sieb. et Zucc.; Japanese cypress)에서 추출한 피톤치드 정유가 구강 내 상주균주이면서 구강 캔디다증을 일으키는 Candida albicans에 미치는 효과를 알아보기 위해 편백 피톤치드와 함께 C. albicans 를 배양한 후, 성장정도, 생존력 및 형태적 변화를 관찰한 결과, 피톤치드는 C. albicans에 강한 항진균력을 보였고, C. albicans에 대한 피톤치드의 최소억제농도(MIC)는 0.25%, 최소살균농도(MFC)는 0.5%였으며, 성장 곡선 상에서, MIC에 근접한 농도의 피톤치드는 C. albicans의 성장을 억제하였다. 피톤치드를 첨가하여 배양한 C. albicans는 투과전자현미경 상에서, MIC 농도에서 대다수의 세포가 세포질 내 전자밀도가 높은 과립물질과 공포를 보이는 비전형적인 형태를 보였다. 이상의 결과로, 피톤치드는 C. albicans에 대해 살균작용에 의한 항진균효과를 갖고 있는 것으로 판단된다. 따라서, 피톤치드의 항진균력은 구강 내 상주균주이면서 특별한 경우에 구강 캔디다증을 일으키는 C. albicans에 유효하게 작용하며, 이를 이용한 구강 위생용품의 적용으로 구강 캔디다증의 예방과 치료 및 예후관리에도 매우 유용하게 사용되리라고 생각된다.

화학요법을 받는 암환자의 구강간호 실태조사연구 -서울시내 종합병원을 중심으로- (The survey of mouth care among cancer patient received chemotherapy)

  • 변영순;김애경
    • 기본간호학회지
    • /
    • 제2권2호
    • /
    • pp.115-130
    • /
    • 1995
  • The incidence of oral complications among adult cancer patients undergoing chemotherapy varies from 12 to 80%. Adequate oral hygiene has been shown to be important in prevention of oral complication and an essential role is reserved for the nursing staff. These considerations prompted the decision to survey by means of a questionaire, the nurses who give care to cancer patients. The Questions were included multidisciplinary treatment, inspection skill, nursing intervention, nursing education, problem in mouth care, solution for problem solving. - Results are fellow : 1. A total of 116 of the nurses returned the questionaire 2. According to 88.2% of the respondents, the policy with regard to oral-hygine is determined by the physician and the nurse. 62.1% of nurses do not consult the dentist When oral complication is occured. 3. In only 34.5% of case was a penight used to provide the necessary extra illumination nursing Inspection of oral cavity. 4. Frequency of oral complications observed by the respondents is that they observed complications in < 25% of patients. The nature of the complication varied from ulcer, stomatitis, infection, dry mouth, candidiasis, herpes simplix, bleeding. 5. Percentages of respondents who use the intervention indicated 1) to prevent oral complication : 0.9% normal saline gargling(44%), 0.02% chlorhexidine gargling, oral dressing(38.8%), observation, nutrition, restriction of alcohol and tabaco(23.2%) 2) to deal with the early symptoms 0.9% normal saline gargling (47.4%), cryotherapy(37.9%), 0.02% chlorhexidine gargling(20.7%) 3) to help alleviate severe complications : dental consult, holding the chemotherapy(34.5%), 0.9% normal saline gargling(31.1%), cryotherapy(18.0%) 6. According to 70% of the respondents, insufficient attention is given to oral complication during nursing education classes only 8.6% said that both the theory and the practical aspects had been deal with in sufficient detail during their training. The results of the survey indicate thatoral care in cancer patients undergoing chemothrapy has a number of problem. There are not enough dentist to provide the necessary care for patients undergoing chemotherapy. The expertise of the nurses with respect to the pathogenesis of the complication is limited. In the training of nurses, additional attention to oral examinations and oral hygine is warranted. The care of patients should be the responsibility of a multidisciplinary team approach. The nurse occupies a key position with in this team, which includes the medical oncologist, a dentist.

  • PDF

구강건조증에 대한 필로카핀 구강양치액의 효과 (Effect of Pilocarpine Mouthwash on Xerostomia)

  • 김지현;박주현;권정승;안형준
    • Journal of Oral Medicine and Pain
    • /
    • 제36권1호
    • /
    • pp.21-24
    • /
    • 2011
  • 구강건조증이란 주관적인 구강 내 건조감으로 정의되며, 이는 약물, 타액선 질환, 방사선 치료, 쉐그렌 증후군, 심리적 요인 등과 같은 다양한 원인에서 비롯된다. 구강 건조증 환자 중 현저한 타액선 기능 감소가 존재하는 경우 구강캔디다증, 치아우식증, 치주질환, 미각변화, 구취 등의 병발증이 나타날 수 있다. 이러한 구강건조증의 치료로는 우선적으로 구강건조를 유발하는 원인요소를 제거하거나, 환자의 불편감을 감소시키기 위한 대증요법이 주가 되며 실제로 타액 분비 기능이 감소된 경우 이로 인한 합병증을 예방하기 위한 치료와 타액분비를 자극할 수 있는 약물치료를 시행할 수 있다. 이 중 타액분비를 촉진시키는 약물인 필로카핀은 구강건조증 치료제로 널리 사용되어 왔다. 하지만 발한작용, 비뇨기 및 위장관계의 비정상적인 기능유도, 심혈관계 및 호흡기계에 대한 위험 등의 부작용이 있어 천식, 만성폐질환, 심혈관계 질환자에게는 주의 깊은 사용이 요구되며, 특히 조절되지 않는 천식환자의 경우 필로카핀의 절대적 금기증으로 사용이 금지된다. 이처럼 구강건조증 치료에 있어 필로카핀은 부작용으로 인해 전신적인 투여에 많은 제한이 있다. 따라서, 필로카핀의 부작용을 최소화하기 위해 국소적으로 사용되는 방법 중의 하나인 필로카핀 양치액을 이용하여 치료한 증례를 통해 그 효과를 확인해보고자 하였다.

Multi-locus sequence typing을 이용한 한국에서 분리한 Candida glabrata 임상균주의 유전자 유형 분석 (Genetic Variations of Candida glabrata Clinical Isolates from Korea using Multi-locus Sequence Typing)

  • 강민지;이경은;진현우
    • 생명과학회지
    • /
    • 제30권2호
    • /
    • pp.122-128
    • /
    • 2020
  • Candida albicans가 칸디다 혈증의 주요 원인 균으로 알려져 있지만, 최근에는 non-albicans Candida (NAC)에 의한 심각한 감염이 증가하고 있다. NAC 중에서 C. glabrata는 두 번째로 병원성을 나타내는 원인 균이지만 C. glabrata의 구조, 역학 등의 기본적인 연구는 거의 없는 실정이다. 따라서 본 연구에서는 다양한 유형의 임상 표본으로부터 분리된 총 102개의 C. glabrata균주로 multi-locus sequence typing (MLST)을 수행하였다. FKS, LEU2, NMT1, TRP1, UGP1 및 URA3을 포함한 6개의 하우스키핑 유전자를 증폭하여 염기서열을 분석하였다. 총 3,345개의 DNA 염기서열 중 49개의 가변 염기서열 부위가 발견되었으며, 그 결과 102개의 균주에서 총 12개의 상이한 서열 유형을 확인하였고, 알려지지 않은 서열 유형(USTs) 중 UST1이 가장 많이 나타났다. 이 연구의 결과는 국내 C. glabrata 항생제 처방에 도움이 될 것으로 사료되며, 한국에서 유행하는 C. glabrata에 대한 추가 연구를 위한 기본 역학자료로 사용될 것으로 기대한다.

구강 작열감 증후군에서 클로나제팜의 국소적 적용 (Topical Application of Clonazepam to Burning Mouth Syndrome)

  • 심영주;최종훈;안형준;권정승
    • Journal of Oral Medicine and Pain
    • /
    • 제34권4호
    • /
    • pp.429-433
    • /
    • 2009
  • 구강 작열감 증후군은 혀나 구강점막에 객관적인 이상징후(abnormal sign)를 보이지 않으면서 혀 및 구강점막의 지속적인 통증을 보이는 만성 질환이다. 연관된 것으로 추정되는 요인이 다양하고 환자마다 통증 양상이 다소 다르게 나타날 수 있어 적절한 진단 및 효과적인 치료를 제공하기 어려운 경우가 많다. 혀나 구강점막의 작열감은 알러지, 캔디다감염, 부기능습관, 타액선 기능저하 등과 같은 국소요인과 당뇨병, 갑상선기능저하증, 영양결핍 등과 같은 전신적 요인, 그리고 우울증, 걱정, 암공포증 등과 같은 심인성 요인과 연관되어 발생할 수 있다. 그러므로, 임상가들은 작열감을 유발할 수 있는 원인들에 대하여 숙지하고 있어야 하며, 혈액검사 등의 관련 검사를 통한 적절한 평가를 정확하고 세심하게 시행하여 효과적인 치료를 제공할 수 있어야 한다. 이러한 구강 작열감 증후군의 치료에는 약물요법, 인지행동요법, 심리치료 등 다양한 치료들이 시도되어지고 있다. 현재 구강작열감 증후군의 치료에 이용되고 있는 약물에는 클로나제팜(clonazepam), 가바펜틴(gabapentin), 삼환성항우울제(amitriptyline), 알파리포산(alpha-lipoic acid), 캡사이신(capsaicin) 등이 보고되고 있으며, 이 중 클로나제팜을 국소적으로 적용하는 것이 전신 투여하는 다른 약물에 비해 부작용이 적으면서 효과도 상당히 좋은 것으로 보고되고 있다. 이에 구강 작열감 증후군 환자에게 클로나제팜을 국소적으로 적용한 증례를 통해 그 효과를 확인하고자 하였다.